PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 24, 20260 citationsOpen Access

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy

View Full Paper
JJJung Yeon JooYJYONG HYUN JUNSKSeong Taeck Kim

Key Points

  • To compare the effectiveness of brolucizumab and bevacizumab in treating chronic central serous chorioretinopathy.
  • Patients with cCSC were assigned to either bevacizumab or brolucizumab groups.
  • Outcomes measured included resolution of subretinal fluid, best-corrected visual acuity, central macular thickness, and subfoveal choroidal thickness.
  • Statistical comparisons were made between groups at different time points.
  • Brolucizumab showed a statistically significant higher resolution of subretinal fluid compared to bevacizumab (P<0.05).
  • In one month, central macular thickness significantly reduced in the brolucizumab group (265±69 μm) compared to the bevacizumab group (319±70 μm) with P=0.021.
  • No significant differences in central macular thickness were observed between groups at two and three months (P>0.05).

Abstract

AIM: To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy (cCSC). METHODS: Patients with cCSC were classified into bevacizumab and brolucizumab group. The proportion of complete resolution of subretinal fluid (SRF), best-corrected visual acuity (BCVA), central macular thickness (CMT), and subfoveal choroidal thickness (SFCT) were compared between the two groups. RESULTS: A total of 40 eyes from 40 patients with aged 34-59y were enrolled in the study. Twenty eyes in bevacizumab group (17 males) and 20 eyes (18 males) in brolucizumab group. Comparing the proportion of complete resolution of SRF, the brolucizumab group was statistically significantly higher than the bevacizumab group (P0.05). CONCLUSION: Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Joo et al. (2026) studied this question.

synapsesocial.com/papers/69746149bb9d90c67120b197https://doi.org/10.18240/ijo.2026.02.14
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy: A Pilot Study2025
  2. 2Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study2025 · 4 citations
  3. 3Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy)2026
  4. 4Comparison between Focal Laser Photocoagulation and Intravitreal Bevacizumab Injection for Treating Chronic Central Serous Chorioretinopathy2024
  5. 5THE OUTCOME OF INTRAVITREAL BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT2024